Genetic medicines platform (formerly GenEdit, founded 2016): NanoGalaxy non-viral non-lipid hydrophilic nanoparticle delivery system to immune cells, heart, lungs, CNS; BRZ-101 IND-enabling for Type 1 Diabetes; multi-year Genentech autoimmune collaboration; cumulative $84M+ across $24M Series A1 (Jan 2024) and $60M Series B